NeuPath Health Inc. (TSXV:NPTH)
| Market Cap | 31.34M +60.5% |
| Revenue (ttm) | 88.97M +12.0% |
| Net Income | 1.34M |
| EPS | 0.02 |
| Shares Out | 56.98M |
| PE Ratio | 24.43 |
| Forward PE | 6.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,500 |
| Open | 0.5500 |
| Previous Close | 0.5600 |
| Day's Range | 0.5500 - 0.5600 |
| 52-Week Range | 0.3200 - 0.6800 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 0.82 (+49.09%) |
| Est. Earnings | Nov 13, 2026 |
About NeuPath Health
NeuPath Health Inc. provides chronic pain management services in Canada. It operates a network of medical clinics in Ontario and Alberta that offer assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports-related injuries, and concussions. The company also provides workplace health services and independent medical assessments to employers and disability insurers, as well as legal practices through a network of health care providers comprising cardiologists, dentists, dermatologists, psychiatri... [Read more]
Financial Performance
In 2025, NeuPath Health's revenue was 87.19 million, an increase of 19.76% compared to the previous year's 72.81 million. Losses were -717,000, -1.51% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NPTH stock is "Buy." The 12-month stock price target is $0.82, which is an increase of 49.09% from the latest price.
News
NeuPath Health Earnings Call Transcript: Q2 2026
Revenue grew 7% year-over-year to CAD 23.2 million in Q2 2026, with adjusted EBITDA up 3% and record patient visits. Capacity utilization improved, new physicians were onboarded, and growth investments are accelerating.
NeuPath Health Earnings release: Q2 2026
NeuPath Health released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
NeuPath Health MD&A: Q2 2026
NeuPath Health filed a regulatory document on August 13, 2026 disclosing important business information.
NeuPath Health Report: Q2 2026
NeuPath Health published a report on August 13, 2026 containing material business information for investors and shareholders.
NeuPath Health Slides: Q2 2026
NeuPath Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
NeuPath Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% revenue growth and 15% Adjusted EBITDA growth, with strong patient volume and capacity utilization gains. Expansion continues with a new Guelph facility and ongoing M&A activity, while gross margin faced pressure from higher staffing costs.
NeuPath Health Earnings release: Q1 2026
NeuPath Health released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
NeuPath Health Report: Q1 2026
NeuPath Health published a report on May 14, 2026 containing material business information for investors and shareholders.
NeuPath Health MD&A: Q1 2026
NeuPath Health filed a regulatory document on May 14, 2026 disclosing important business information.
NeuPath Health Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
A leading chronic pain clinic network reported 20% revenue growth and strong EBITDA margins, driven by increased physician hours, technology investments, and a robust M&A strategy. The business benefits from a highly fragmented market, low physician churn, and over 90% government-insured revenue.
NeuPath Health Earnings Call Transcript: Q4 2025
Revenue grew 20% to CAD 87.2M in 2025, with adjusted EBITDA up 56% and margin improvement. Growth is driven by physician recruitment, technology, and service expansion, with 2026 guidance for 8%-12% revenue growth and higher EBITDA margin.
NeuPath Health Earnings release: Q4 2025
NeuPath Health released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
NeuPath Health Report: Q4 2025
NeuPath Health published a report on March 26, 2026 containing material business information for investors and shareholders.
NeuPath Health MD&A: Q4 2025
NeuPath Health filed a regulatory document on March 26, 2026 disclosing important business information.
NeuPath Health Annual report: Q4 2025
NeuPath Health has published its Q4 2025 annual report on March 26, 2026.
NeuPath Health Slides: Investor presentation
NeuPath Health has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
NeuPath Health Earnings Call Transcript: Q3 2025
Q3 saw 26% revenue growth and a 98% increase in adjusted EBITDA, driven by higher patient volumes and operational improvements. The company reduced net debt, expanded in Alberta, and is actively pursuing acquisitions, with a strong cash position and ongoing share buybacks.
NeuPath Health Earnings release: Q3 2025
NeuPath Health released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
NeuPath Health Report: Q3 2025
NeuPath Health published a report on November 13, 2025 containing material business information for investors and shareholders.
NeuPath Health MD&A: Q3 2025
NeuPath Health filed a regulatory document on November 13, 2025 disclosing important business information.